An ongoing dialogue on HIV/AIDS, infectious diseases,
March 10th, 2009
Unwelcome Visitor: Cost of HIV Meds
Those of us who practice HIV medicine in Taxachusetts (warning, click link at your peril) live a pretty charmed life, at least so far as getting HIV medications paid for. Due to an incredibly generous AIDS Drug Assistance Program (ADAP), rare is the patient who faces financial barriers getting his or her drugs.
(By the way, we abbreviate it “HDAP” here, not ADAP. And we treat early syphilis with two shots of penicillin, not one. And we voted for McGovern. And we drive on the left.)
But the recent downturn in the economy has changed this usually comfortable situation in the Bay State.
A patient of mine called to tell me that his co-pay for a 3 month supply of his antivirals is now nearly $2000. Another one has simply stopped coming to appointments, as his wife’s insurance has such a large deductible that he will only agree to blood tests, not an actual office visit. A third asked me whether he would be better off stopping enoxaparin or his HIV meds, since he couldn’t afford both.
I am sure things are much worse in other States — after all, Houston’s Joe Gathe initially tried lopinavir/r monotherapy since he reasoned that some ART was better than none, and his patients couldn’t afford triple-therapy.
Where is this headed? It’s tough to make predictions (especially about the future), but I suspect that when 3TC and saquinavir become generic, we might be turning to them more often than we’d previously thought.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Andes Hantavirus Outbreak on a Cruise Ship, 2026 June 25, 2026On May 2, hantavirus infection was diagnosed in a patient who had been on a cruise ship. Subsequent evaluation revealed multiple cases of Andes hantavirus infection on the ship. To date, three associated deaths have occurred.
- Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection June 25, 2026In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo.
- Clusters of Concern — Spatial Link between Childhood Undervaccination and Measles Outbreaks in South Carolina June 25, 2026Spatial analysis in South Carolina revealed that measles infections were clustered in areas where public school vaccination rates were lower.
- Improving Global Air-Quality Indices — The WHO’s New Roadmap June 25, 2026Many countries rely on air-quality indices to inform the public and help protect people during short-term increases in air pollution. Their use has important societal and economic implications.
- A Major Step toward a Cure for Hepatitis B Infection June 25, 2026The current treatment of chronic hepatitis B infection includes nucleoside or nucleotide analogue (NA) therapy and pegylated interferon. Both of these treatments are effective in suppressing hepatitis B virus (HBV) replication and in reducing the risk of cirrhosis and hepatocellular carcinoma.1 However, these treatments do not eradicate HBV,...
- Andes Hantavirus Outbreak on a Cruise Ship, 2026 June 25, 2026